Total raised
$2.0M
Last: Seed 2021-01
Stage
Seed
Founded
2019
Headcount
6
HQ
Caesarea
Sector
Health Tech & Life Sciences
About
Elixie is a clinical-stage biotech company enhancing cannabinoids for symptomatic relief of neurological disorders based on NANOLIX, a patented clinically proven Self-nano emulsifying drug delivery system (SNEDDS).
By encapsulating validated APIs in in-human-proven NANOLIX and targeting orphan diseases, Elixie will register pharmaceuticals in a relatively short route to market and with minimal risks.
Funding history · 1 round · $2.0M total
2021-01
Seed
$2.0M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyMedical CannabisDrug Delivery
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients
Business model
B2B2CB2B
Highlights
1 PatentsVerified
Tags
chronic-painnanotechnologymultiple-sclerosisdrug-deliverycannabispharma-companiesmedical-technologiespharmaceuticalsepilepsychronic-diseasemedical-cannabis